Methods of and apparatus for treatment with flash radiotherapy
The present disclosure relates to the field of radiotherapy, in particular, methods of and apparatus for treating cancer using ultra-high dose rate radiotherapy (FLASH). The apparatus may comprise a device configured to administer to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively. The device may be configured such that the treatment is sufficient to prevent further growth of the tumor for at least 10% longer than standard of care radiotherapy, induce at least 10% more tumor regression than standard of care radiotherapy and/or delay tumor regrowth by at least about 2 months longer than standard of care radiotherapy.
1. A method for treating cancer in a subject, the method comprising administering to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively, wherein the treatment is sufficient to prevent further growth of a tumor for at least 10% longer than standard of care radiotherapy.
2. The method of claim 1 , wherein a dose of proton FLASH is equitoxic to a dose of conventional dose rate radiotherapy.
3. The method of claim 1 , wherein the collective dose of radiation delivered by proton FLASH radiotherapy is contraindicated in the subject.
4. The method of claim 1 , wherein the collective dose of radiation delivered by proton FLASH to the tumor is about 1.1 times, 1.2 times, 1.5 times, about 2 times, about 3 times, about 4 times, about 5 times, about 10 times or about 15 times a dose of conventional dose rate radiotherapy indicated for the cancer.
5. The method of claim 1 , wherein the collective dose of radiation delivered to the tumor is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% higher than a dose of conventional dose rate radiotherapy indicated for the cancer.
6. The method of claim 1 , wherein the cancer is a cancer for which radiotherapy is not indicated.
7. The method of claim 1 , wherein the cancer is lung cancer, head and neck cancer, brain cancer, breast cancer or skin cancer.
8. The method of claim 1 , wherein the subject is human.
9. A method for treating cancer in a subject, the method comprising administering to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively, wherein the treatment is sufficient to induce at least 10% more tumor regression than standard of care radiotherapy.
10. The method of claim 9 , wherein a dose of proton FLASH is equitoxic to a dose of conventional dose rate radiotherapy.
11. The method of claim 9 , wherein the collective dose of radiation delivered by proton FLASH radiotherapy is contraindicated in the subject.
12. The method of claim 9 , wherein the collective dose of radiation delivered by proton FLASH to the tumor is about 1.1 times, 1.2 times, 1.5 times, about 2 times, about 3 times, about 4 times, about 5 times, about 10 times or about 15 times a dose of conventional dose rate radiotherapy indicated for the cancer.
13. The method of claim 9 , wherein the collective dose of radiation delivered to the tumor is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% higher than a dose of conventional dose rate radiotherapy indicated for the cancer.
14. The method of claim 9 , wherein the cancer is a cancer for which radiotherapy is not indicated.
15. The method of claim 9 , wherein the cancer is lung cancer, head and neck cancer, brain cancer, breast cancer or skin cancer.
16. A method for treating cancer in a subject, the method comprising administering to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively, wherein the treatment results in at least 10% less, at least 20% less, at least 30% less, at least 40% less, at least 50% less, at least 60% less, at least 70% less, at least 80% less, or more than 80% less healthy tissue toxicity than standard of care radiotherapy.
17. The method of claim 16 , wherein the healthy tissue toxicity is skin toxicity, muscle toxicity, or neurotoxicity.
18. The method of claim 16 , wherein the collective dose of radiation delivered by proton FLASH radiotherapy is contraindicated in the subject.
19. The method of claim 16 , wherein the collective dose of radiation delivered by proton FLASH to the tumor is about 1.1 times, 1.2 times, 1.5 times, about 2 times, about 3 times, about 4 times, about 5 times, about 10 times or about 15 times a dose of conventional dose rate radiotherapy indicated for the cancer.
20. The method of claim 16 , wherein the collective dose of radiation delivered to the tumor is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% higher than a dose of conventional dose rate radiotherapy indicated for the cancer.
21. The method of claim 16 , wherein the cancer is a cancer for which radiotherapy is not indicated.
22. The method of claim 16 , wherein the cancer is lung cancer, head and neck cancer, brain cancer, breast cancer or skin cancer.
23. A method of treating brain cancer in a subject, the method comprising administering to the subject a total dose of about 10 Gy to about 60 Gy proton FLASH radiotherapy in five fractions or less at a dose rate of 40 Gy/sec or higher, wherein the cancer is brain cancer, heard and neck cancer, or breast cancer.